IDH1 and central nervous system cancer: In the majority of glioblastoma/glioma studies (Table 1), high NLR was established as an independent factor for worse outcomes without including MGMT promoter methylation status, steroid use, IDH mutation status, or other prognostic variables in multivariate analyses.